HomeBUSINESS
BUSINESS

Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
(Oct.3.2018)

Belén Garijo, CEO, Healthcare Business, Merck KGaA
Merck KGaA’s PD-L1 inhibitor Bavencio (avelumab) might be facing an uphill battle, but healthcare business chief Belén Garijo says that the German heavyweight believes it can still catch up in the immuno-oncology arena with its promising next-generation therapy M7824 ...
(LOG IN FOR FULL STORY)